MARKET

EIDX

EIDX

Eidos Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.27
+1.23
+2.56%
Closed 16:00 07/02 EDT
OPEN
48.81
PREV CLOSE
48.04
HIGH
49.77
LOW
48.13
VOLUME
49.02K
TURNOVER
--
52 WEEK HIGH
66.56
52 WEEK LOW
28.00
MARKET CAP
1.90B
P/E (TTM)
-37.5877
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EIDX stock price target is 56.43 with a high estimate of 80.00 and a low estimate of 34.00.

EPS

EIDX News

More
Hedge Funds Are Dumping Eidos Therapeutics, Inc. (EIDX)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 16h ago
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session
Zacks · 4d ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eidos Therapeutics, Inc. - EIDX
Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX). The investigation concerns whether Eidos and certain of its officers and/or directors have breached fiduciary duties owed to th
GlobeNewswire · 06/11 01:13
Benzinga's Top Upgrades, Downgrades For May 14, 2020
Upgrades
Benzinga · 05/14 13:31
10 Biggest Price Target Changes For Thursday
Credit Suisse raised the price target on McCormick & Company, Incorporated (NYSE: MKC) from $147 to $187. McCormick shares closed at $168.52 on Wednesday.
Benzinga · 05/14 12:01
JP Morgan Downgrades Eidos Therapeutics to Neutral, Lowers Price Target of $50
JP Morgan analyst Anupam Rama downgrades Eidos Therapeutics (NASDAQ:EIDX) from Overweight to Neutral and lowers the price target from $58 to $50.
Benzinga · 05/14 09:32
Barclays Maintains Underweight on Eidos Therapeutics, Lowers Price Target to $34
Barclays maintains Eidos Therapeutics (NASDAQ:EIDX) with a Underweight and lowers the price target from $45 to $34.
Benzinga · 05/11 15:36
SVB Leerink Maintains Outperform on Eidos Therapeutics, Lowers Price Target to $59
SVB Leerink maintains Eidos Therapeutics (NASDAQ:EIDX) with a Outperform and lowers the price target from $62 to $59.
Benzinga · 05/11 10:27

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About EIDX

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
More

Webull offers kinds of Eidos Therapeutics Inc stock information, including NASDAQ:EIDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIDX stock methods without spending real money on the virtual paper trading platform.